Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer CohortMakoto Nishio, Koichi Azuma, Hisato Kawakami et al.|Cancer Research Communications|2024Cited by 4